A Randomized, Double Blinded, Placebo Controlled Multicenter Phase III Study of Apatinib Mesylate Tablets in the Treatment of Advanced or Metastatic Gastric Cancer
Phase of Trial: Phase III
Latest Information Update: 23 Jun 2016
At a glance
- Drugs Rivoceranib (Primary)
- Indications Gastric cancer
- Focus Registrational; Therapeutic Use
- Sponsors Jiangsu Hengrui Medicine Co.
- 16 Feb 2016 Results published in the Journal of Clinical Oncology
- 03 Jun 2014 Primary endpoint 'Overall-survival-duration' has been met.
- 03 Jun 2014 Results presented at the 50th Annual Meeting of the American Society of Clinical Oncology.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History